624 related articles for article (PubMed ID: 28438889)
21. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
[TBL] [Abstract][Full Text] [Related]
22. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
[TBL] [Abstract][Full Text] [Related]
23. Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource-constrained setting.
Chan TSY; Hwang YY; Khong PL; Leung AYH; Chim CS; Tse EWC; Kwong YL
Hematol Oncol; 2020 Dec; 38(5):726-736. PubMed ID: 32786092
[TBL] [Abstract][Full Text] [Related]
24. Remission of relapsed/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem cell transplantation: a case report.
Giannotti F; De Ramon Ortiz C; Simonetta F; Morin S; Bernardi C; Masouridi-Levrat S; Chalandon Y; Mamez AC
Front Immunol; 2024; 15():1360275. PubMed ID: 38510239
[TBL] [Abstract][Full Text] [Related]
25. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM
Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817
[TBL] [Abstract][Full Text] [Related]
26. Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab.
Villasboas JC; Ansell SM
Expert Rev Anticancer Ther; 2016; 16(1):5-12. PubMed ID: 26577822
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma.
Fedorova LV; Lepik KV; Volkov NP; Kotselyabina PV; Borzenkova ES; Popova MO; Beynarovich AV; Baykov VV; Kozlov AV; Moiseev IS; Mikhailova NB; Kulagin AD
Int J Clin Oncol; 2022 Mar; 27(3):626-632. PubMed ID: 34826011
[TBL] [Abstract][Full Text] [Related]
28. Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab.
Gay ND; Okada CY; Chen AI; Scott EC
Ther Adv Hematol; 2017 May; 8(5):175-180. PubMed ID: 28473905
[TBL] [Abstract][Full Text] [Related]
29. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
[TBL] [Abstract][Full Text] [Related]
30. Development of Resistant GvHD in a Patient Treated with Nivolumab for Hodgkins Lymphoma Relapse after Allogeneic Unrelated Transplantation.
Steinerová K; Jindra P; Lysák D; Karas M
Klin Onkol; 2019; 32(1):66-69. PubMed ID: 30764632
[TBL] [Abstract][Full Text] [Related]
31. Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience.
Moretti M; Liberati AM; Rigacci L; Puccini B; Pulsoni A; Gini G; Galieni P; Fabbri A; Cantonetti M; Pavone V; Bolis S; Botto B; Renzi D; Falchi L
Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):198-204. PubMed ID: 34690088
[TBL] [Abstract][Full Text] [Related]
32. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.
Bonthapally V; Wu E; Macalalad A; Yang H; Shonukan O; Liu Y; Chi A; Huebner D
Curr Med Res Opin; 2015 May; 31(5):993-1001. PubMed ID: 25772232
[TBL] [Abstract][Full Text] [Related]
33. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes.
Cheah CY; Chihara D; Horowitz S; Sevin A; Oki Y; Zhou S; Fowler NH; Romaguera JE; Turturro F; Hagemeister FB; Fayad LE; Wang M; Neelapu SS; Nastoupil LJ; Westin JR; Rodriguez MA; Samaniego F; Anderlini P; Nieto Y; Fanale MA
Ann Oncol; 2016 Jul; 27(7):1317-23. PubMed ID: 27091808
[TBL] [Abstract][Full Text] [Related]
34. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study.
Ansell SM; Bröckelmann PJ; von Keudell G; Lee HJ; Santoro A; Zinzani PL; Collins GP; Cohen JB; de Boer JP; Kuruvilla J; Savage KJ; Trněný M; Provencio M; Jäger U; Willenbacher W; Wen R; Akyol A; Mikita-Geoffroy J; Shipp MA; Engert A; Armand P
Blood Adv; 2023 Oct; 7(20):6266-6274. PubMed ID: 37530622
[TBL] [Abstract][Full Text] [Related]
35. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P
N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239
[TBL] [Abstract][Full Text] [Related]
36. [Brentuximab vedotin treatment in patients with relapsed or refractory Hodgkin lymphoma. A Hungarian retrospective study].
Molnár Z; Pinczés LI; Piukovics K; Istenes I; Wolf K; Csukly Z; Szomor Á; Illés Á; Miltényi Z
Orv Hetil; 2017 Oct; 158(41):1630-1634. PubMed ID: 29025292
[TBL] [Abstract][Full Text] [Related]
37. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party.
Bazarbachi A; Boumendil A; Finel H; Mohty M; Castagna L; Blaise D; Peggs KS; Afanasyev B; Diez-Martin JL; Corradini P; Michonneau D; Robinson S; Gutiérrez García G; Bonifazi F; Yakoub-Agha I; Gülbas Z; Bloor A; Delage J; Esquirol A; Malladi R; Scheid C; El-Cheikh J; Ghesquières H; Montoto S; Dreger P; Sureda A
Cancer; 2019 Jan; 125(1):90-98. PubMed ID: 30351488
[TBL] [Abstract][Full Text] [Related]
38. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
[TBL] [Abstract][Full Text] [Related]
39. Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma.
Greve P; Beishuizen A; Hagleitner M; Loeffen J; Veening M; Boes M; Peperzak V; Diez C; Meyer-Wentrup F
Front Immunol; 2023; 14():1229558. PubMed ID: 37583696
[TBL] [Abstract][Full Text] [Related]
40. Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma.
Ishizawa K; Yanai T
Adv Ther; 2019 Oct; 36(10):2679-2696. PubMed ID: 31392578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
